Indianapolis, IN, United States of America

Donald R Gehlert


Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 73(Granted Patents)


Company Filing History:


Years Active: 1994-2003

Loading Chart...
12 patents (USPTO):Explore Patents

Title: **Donald R Gehlert: Innovator in Pharmaceutical Sciences**

Introduction

Donald R Gehlert is a distinguished inventor based in Indianapolis, IN, with a notable portfolio of 12 patents. His contributions primarily focus on innovative methods that address physiological conditions through cutting-edge pharmaceuticals.

Latest Patents

Gehlert's latest inventions include methods for inhibiting physiological conditions associated with an excess of neuropeptide Y. This particular innovation revolves around indolyl neuropeptide Y receptor antagonists. The invention introduces a series of substituted indoles that are instrumental in treating or preventing conditions linked to an overabundance of neuropeptide Y. It also provides novel pharmaceutical formulations containing these substituted indoles as active ingredients, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Gehlert has made significant strides in the field of pharmaceuticals, particularly while working at Eli Lilly and Company, a leading global healthcare company. His innovative research and development efforts have been pivotal in enhancing therapeutic options available to patients, establishing him as a key player in the industry.

Collaborations

Donald Gehlert has collaborated with other notable professionals, including Robert F Bruns, Jr and J Jeffry Howbert. These collaborations have fostered a creative environment, allowing for the exchange of ideas and advancements in their shared field of study. Together, they have contributed to the ongoing evolution of pharmaceutical innovations.

Conclusion

In conclusion, Donald R Gehlert exemplifies the spirit of innovation within the pharmaceutical sector. His array of patents and collaborative efforts underscore his impact on healthcare advancements. As he continues to work with Eli Lilly and Company, his contributions will undoubtedly pave the way for future breakthroughs in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…